Heparin-mediated selective release of hepatocyte growth factor in humans
- PMID: 10971306
- PMCID: PMC2014977
- DOI: 10.1111/j.1365-2125.2000.00246.x
Heparin-mediated selective release of hepatocyte growth factor in humans
Abstract
Aims: The aim of this investigation was to compare the effects of standard (S) with low molecular weight (LMW) heparin on circulating levels of heparin-binding growth factors (HBGF), known to have angiogenic properties in humans.
Methods: In two consecutive trials 18 healthy male volunteers were studied on three separate occasions, following a placebo-controlled crossover design. Subjects were randomised to receive either S-heparin or LMW heparin or placebo. Heparins were administered either by intravenous (i.v.) or subcutaneous (s.c.) injection and saline placebo by i.v. injection. Serum concentrations of hepatocyte growth factor (HGF), vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) were measured before and up to 24 h after injection.
Results: Administration of i.v. S-or LMW-heparin (50 IU kg(-1) resulted in rapid, highly significant (47 fold for S, 30.9 fold for LMW) increases in HGF serum values, reaching maxima of 10.51+/-1.65 ng ml(-1) (S) and 8.28+/-1.04 ng ml(-1) (LMW), respectively, 10 min after drug application. S.c. injection of S-heparin or LMW heparin resulted in 4.1 and 5.4 fold increases in HGF serum values, respectively. Both agents showed no effects on circulating VEGF or bFGF levels, independent of the route of administration.
Conclusions: Circulating HGF levels were selectively increased in response to pharmacological doses of two, widely used heparin preparations. This may, in part, explain some of the biological effects of heparin separate from its anticoagulant properties. By this mechanism, the systemic administration of heparin may facilitate collateral vessel formation in various clinical settings of tissue ischaemia.
Figures

Similar articles
-
Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.Am J Health Syst Pharm. 2001 Sep 1;58(17):1614-21. doi: 10.1093/ajhp/58.17.1614. Am J Health Syst Pharm. 2001. PMID: 11556655 Clinical Trial.
-
Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7. doi: 10.1006/bbrc.1999.0150. Biochem Biophys Res Commun. 1999. PMID: 10082659
-
Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals.Br J Haematol. 1999 Jun;105(3):641-7. doi: 10.1046/j.1365-2141.1999.01398.x. Br J Haematol. 1999. PMID: 10354124 Clinical Trial.
-
Controlled release of heparin-binding growth factors using heparin-containing particulate systems for tissue regeneration.Expert Opin Drug Deliv. 2008 Nov;5(11):1173-84. doi: 10.1517/17425240802431811. Expert Opin Drug Deliv. 2008. PMID: 18976129 Review.
-
The heparins and cancer: review of clinical trials and biological properties.Vasc Med. 2004 May;9(3):205-13. doi: 10.1191/1358863x04vm566ra. Vasc Med. 2004. PMID: 15675186 Review.
Cited by
-
Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications.BMC Res Notes. 2012 Sep 23;5:517. doi: 10.1186/1756-0500-5-517. BMC Res Notes. 2012. PMID: 22999213 Free PMC article. Clinical Trial.
-
Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use.Molecules. 2015 Apr 10;20(4):6342-88. doi: 10.3390/molecules20046342. Molecules. 2015. PMID: 25867824 Free PMC article. Review.
-
Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke.Stroke. 2018 Feb;49(2):377-383. doi: 10.1161/STROKEAHA.117.019476. Epub 2018 Jan 10. Stroke. 2018. PMID: 29321335 Free PMC article.
-
Heparin/Collagen 3D Scaffold Accelerates Hepatocyte Differentiation of Wharton's Jelly-Derived Mesenchymal Stem Cells.Tissue Eng Regen Med. 2017 May 23;14(4):443-452. doi: 10.1007/s13770-017-0048-z. eCollection 2017 Aug. Tissue Eng Regen Med. 2017. PMID: 30603500 Free PMC article.
References
-
- Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–443. - PubMed
-
- Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Comm. 1997;239:639–644. - PubMed
-
- van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation. 1998;97:381–390. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical